| Symbol | ENTX |
|---|---|
| Name | ENTERA BIO LTD. |
| Sector | HEALTH CARE |
| Region | Middle East |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Address | MINRAV BUILDING - FIFTH FLOOR,KIRYAT HADASSAH, JERUSALEM BIO PARK, JERUSALEM, 9112002, Israel |
| Telephone | +972 25327151 |
| Fax | — |
| — | |
| Website | https://www.enterabio.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001638097 |
| Description | Entera is a clinical stage company focused on developing first-in-class oral peptide and protein replacement therapies in tablet format for significant unmet medical needs. The Company leverages on a disruptive and proprietary technology platform (N-Tab) and its pipeline is focused on GYN/Endocrinology, gastrointestinal rare diseases. EB613 (oral PTH(1-34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with high-risk osteoporosis. EB612 is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Additional info from NASDAQ: |
2026-05-08 20:29
Galitzer Hillel 🟢 acquired 73.0K shares of Entera Bio Ltd. (ENTX) Transaction Date: May 07, 2026 | Filing ID: 002466
Read more
2026-05-08 20:27
Yaacov-Garbeli Dana 🟢 acquired 58.4K shares of Entera Bio Ltd. (ENTX) Transaction Date: May 07, 2026 | Filing ID: 002464
Read more
2026-05-08 20:05
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
Read more
2026-04-14 12:45
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
Read more
2026-04-06 17:50
Greenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF Partners
Read more
2026-04-02 12:45
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
Read more
2026-03-27 20:05
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07113483 | Remimazolam vs. Midazolam for Sedation and Cognitive Outcomes in Orthopedic Sur… | Phase3 | Postoperative Cognitive Dysfunction | Recruiting | 2025-10-01 | 2026-02-15 | ClinicalTrials.gov |
| NCT07057037 | Phase 3 Study of the Efficacy and Safety of MR Arthrography Using the NEMO-103 … | Phase3 | Rotator Cuff Tear | Active_Not_Recruiting | 2025-09-23 | 2026-08-01 | ClinicalTrials.gov |
| NCT06951490 | PillSense Use in Anemia and Hemoccult | — | Occult Gastrointestinal Bleeding | Enrolling_By_Invitation | 2025-05-15 | 2027-06-15 | ClinicalTrials.gov |
| NCT06510348 | Achieving nuTritional Target in criticAlly Ill patieNts With iMpairEd gastroiNt… | Na | Parenteral Nutrition | Recruiting | 2024-10-01 | 2026-12-31 | ClinicalTrials.gov |
| NCT05286177 | Does Volume-based Enteral Feeding Improve Nutrient Delivery in Hospitalized Cri… | Na | Enteral Feeding | Active_Not_Recruiting | 2024-03-20 | 2027-04-01 | ClinicalTrials.gov |
| NCT05965167 | Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP… | Phase1 | Hypoparathyroidism | Completed | 2023-05-11 | 2026-02-08 | ClinicalTrials.gov |
| NCT05647135 | ImpACt of Very High Protein Content Enteral nUtrition Formulas on Critically Il… | — | Metabolism | Recruiting | 2023-03-01 | 2024-12-01 | ClinicalTrials.gov |
| NCT05385224 | PillSense System for Detecting UGI Bleed | Na | UGI Bleed | Completed | 2021-12-10 | 2022-09-13 | ClinicalTrials.gov |
| NCT05127811 | A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma | Phase1 | Non-Hodgkin Lymphoma | Terminated | 2021-10-21 | 2023-05-26 | ClinicalTrials.gov |
| NCT04972422 | A Phase 1b Study of ZN-c3 in Chinese Subjects | Phase1 | Solid Tumors | Unknown | 2021-07-15 | 2023-06-30 | ClinicalTrials.gov |
| NCT04852419 | A PHASE 1B STUDY OF ZN-C5 IN CHINESE SUBJECTS | Phase1 | Breast Neoplasms | Completed | 2021-05-31 | 2022-06-23 | ClinicalTrials.gov |
| NCT05631639 | Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor… | Na | Upper Gastrointestinal Bleeding | Completed | 2021-05-07 | 2021-08-30 | ClinicalTrials.gov |
| NCT05631652 | Detection of Upper Gastrointestinal (GI) Bleeding Using a Novel Bleeding Sensor… | Na | Upper Gastrointestinal Bleeding | Completed | 2021-02-11 | 2021-03-11 | ClinicalTrials.gov |
| NCT04682041 | Evaluating the Impact of EnteraGam In People With COVID-19 | Na | Covid19 | Completed | 2020-12-22 | 2022-02-21 | ClinicalTrials.gov |
| NCT04003467 | A Six-month Phase 2 Study of Oral hPTH(1-34) (EBP05) in Postmenopausal Women Wi… | Phase2 | Osteoporosis | Completed | 2019-06-30 | 2021-05-11 | ClinicalTrials.gov |
| NCT03584399 | Prospective Evaluation of the Incidence of PICS | — | Metabolism and Nutrition Disorder | Terminated | 2019-03-01 | 2020-12-31 | ClinicalTrials.gov |
| NCT03516773 | Oral PTH(1-34) PK and PD Study in Patients With Hypoparathyroidism | Phase2 | Hypoparathyroidism | Completed | 2018-06-17 | 2019-02-24 | ClinicalTrials.gov |
| NCT04072627 | Microbial Composition of Breast Milk Collected From Healthy Turkish Women | — | Microbial Community in Breast Milk | Completed | 2018-05-05 | 2019-07-05 | ClinicalTrials.gov |
| NCT04711564 | The Effects of Different Lipid Emulsions on the Adipokines in Critically Ill Pa… | — | Sepsis | Completed | 2018-03-29 | 2020-04-15 | ClinicalTrials.gov |
| NCT02619812 | Manage Diarrhea in Patients With Multiple Myeloma While Receiving Conditioning … | Phase2 | Multiple Myeloma | Terminated | 2016-04-01 | 2016-12-01 | ClinicalTrials.gov |
| NCT02608658 | Evaluation of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects W… | Na | Cirrhosis of the Liver | Completed | 2016-03-01 | 2017-04-27 | ClinicalTrials.gov |
| NCT02649075 | To Evaluate SBI in the Dietary Management of Mild to Moderate Crohn's Disease | Na | Crohn's Disease | Terminated | 2016-02-01 | 2017-08-01 | ClinicalTrials.gov |
| NCT02730325 | To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients | Na | Clostridium Difficile | Terminated | 2015-12-01 | 2018-01-05 | ClinicalTrials.gov |
| NCT02661425 | Retrospective Study of IBS-D Patients Previously Receiving SBI | — | Diarrhoea Predominant Irritable Bowel Syndrome | Completed | 2015-12-01 | 2016-09-01 | ClinicalTrials.gov |
| NCT02609529 | SBI in Children With d-IBS | Na | Irritable Bowel Syndrome | Completed | 2015-11-01 | 2017-03-02 | ClinicalTrials.gov |
| NCT02251483 | Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal… | Na | Diarrhea Predominant Irritable Bowel Syndrome | Completed | 2014-09-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02152228 | A Pilot Study to Assess the Safety and Efficacy of Oral PTH (1-34) in the Treat… | Phase2 | Hypoparathyroidism | Completed | 2014-07-01 | 2015-07-01 | ClinicalTrials.gov |
| NCT02182427 | Malnutrition Clinical Characteristics Validation Study | — | Malnutrition | Completed | 2014-04-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT02017405 | Study Evaluating the Digestibility of Serum-Derived Bovine Immunoglobulin Prote… | Na | Healthy | Completed | 2013-12-01 | 2014-11-01 | ClinicalTrials.gov |
| NCT02067377 | Efficacy of Serum Bovine Immunoglobulin in Improving Nutritional Status in Adva… | Na | Advanced COPD (GOLD Stage 3 or 4) With Cachexia | Completed | 2013-12-01 | — | ClinicalTrials.gov |
| NCT02571140 | A Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of Oral PTH… | Phase1 | Drug Safety and Bioavailability | Completed | 2013-10-01 | 2017-10-01 | ClinicalTrials.gov |
| NCT01828593 | Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-assoc… | Na | HIV-associated Enteropathy | Completed | 2013-04-01 | 2014-09-01 | ClinicalTrials.gov |
| NCT02202603 | A Three Stage, Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic… | Phase1 | Drug Safety | Completed | 2011-07-01 | 2013-08-01 | ClinicalTrials.gov |
| NCT01760408 | Sustain, A.S.P.E.N. HPN Registry 2011 | — | Patients Requiring Home Parenteral Nutrition | Completed | 2011-02-01 | 2015-02-01 | ClinicalTrials.gov |
| NCT00441038 | A Trial on the Effect on Low Back Pain Related Disability of Different Health E… | Na | Low Back Pain | Withdrawn | 2006-12-01 | 2008-09-01 | ClinicalTrials.gov |
| NCT00351533 | A Phase II Randomized Trial of Fish Oil in Patients With Acute Lung Injury (ALI) | Phase2 | Respiratory Distress Syndrome, Adult | Completed | 2006-07-01 | 2009-08-01 | ClinicalTrials.gov |
| NCT00314834 | Effect of Intradialytic Parenteral Nutrition on Morbidity and Mortality of Maln… | Phase4 | Hemodialysis | Terminated | 2001-01-01 | 2004-12-01 | ClinicalTrials.gov |
Total clinical trials: 37
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Placebo | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT02609529 |
| Medical Food | Other | Approved | Irritable Bowel Syndrome | COMPLETED | NCT02609529 |
| Placebo | Other | Approved | Crohn's Disease | TERMINATED | NCT02649075 |
| Serum-derived Bovine Immunoglobulin / Protein Isolate | Other | Approved | Crohn's Disease | TERMINATED | NCT02649075 |
| Intradialytic parenteral nutrition | Other | Phase PHASE4 | Hemodialysis | TERMINATED | NCT00314834 |
| Intradialytic parenteral nutrition | Other | Phase PHASE4 | Hemodialysis | TERMINATED | NCT00314834 |
| Fish oil (eicosapentaenoic acid and docosahexanoic acid) | Other | Phase PHASE2 | Respiratory Distress Syndrome, Adult | COMPLETED | NCT00351533 |
| Fish oil (eicosapentaenoic acid and docosahexanoic acid) | Other | Phase PHASE2 | Respiratory Distress Syndrome, Adult | COMPLETED | NCT00351533 |
| Placebo | Other | Approved | Diarrhea Predominant Irritable Bowel Syndrome | COMPLETED | NCT02251483 |
| Serum-derived bovine immunoglobulin protein isolate (SBI) | Other | Approved | Diarrhea Predominant Irritable Bowel Syndrome | COMPLETED | NCT02251483 |
| placebo | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT02202603 |
| Teriparatide | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT02202603 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT02152228 |
| Placebo (for serum bovine immunoglobulin) | Other | Approved | Advanced COPD (GOLD Stage 3 or 4) With Cachexia | COMPLETED | NCT02067377 |
| Serum bovine immunoglobulin (SBI) medical food | Other | Approved | Advanced COPD (GOLD Stage 3 or 4) With Cachexia | COMPLETED | NCT02067377 |
| EnteraGam | Other | Preclinical | Diarrhoea Predominant Irritable Bowel Syndrome | COMPLETED | NCT02661425 |
| all patients on Home Parenteral Nutrition | Other | Preclinical | Patients Requiring Home Parenteral Nutrition | COMPLETED | NCT01760408 |
| all patients on Home Parenteral Nutrition | Other | Preclinical | Patients Requiring Home Parenteral Nutrition | COMPLETED | NCT01760408 |
| Double Placebo | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02619812 |
| Colesevelam | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02619812 |
| Serum-derived bovine immunoglobulin/protein isolate (SBI) | Other | Phase PHASE2 | Multiple Myeloma | TERMINATED | NCT02619812 |
| Placebo | Other | Approved | HIV-associated Enteropathy | COMPLETED | NCT01828593 |
| Serum-derived bovine immunoglobulin protein isolate (SBI) | Other | Approved | HIV-associated Enteropathy | COMPLETED | NCT01828593 |
| Oral PTH (1-34) | Other | Phase PHASE1 | Drug Safety and Bioavailability | COMPLETED | NCT02571140 |
| Teriparatide | Other | Phase PHASE1 | Drug Safety and Bioavailability | COMPLETED | NCT02571140 |
| Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin) | Other | Approved | Cirrhosis of the Liver | COMPLETED | NCT02608658 |
| NATPARA/NATPAR | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT03516773 |
| EB612 (EBP05) | Other | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT03516773 |
| Soybean-based intravenous fat emulsions | Other | Preclinical | Sepsis | COMPLETED | NCT04711564 |
| Olive oil-based intravenous fat emulsions | Other | Preclinical | Sepsis | COMPLETED | NCT04711564 |
| Soybean-based intravenous fat emulsions | Other | Preclinical | Sepsis | COMPLETED | NCT04711564 |
| Olive oil-based intravenous fat emulsions | Other | Preclinical | Sepsis | COMPLETED | NCT04711564 |
| Cardiovascular and general health | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Book | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Guide | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| Cardiovascular and general health | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Book | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Guide | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| Cardiovascular and general health | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Book | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| The Back Guide | Other | Approved | Low Back Pain | WITHDRAWN | NCT00441038 |
| Placebo of EBP05 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT04003467 |
| EBP05 | Other | Phase PHASE2 | Osteoporosis | COMPLETED | NCT04003467 |
| ZN-c3 | Other | Phase PHASE1 | Solid Tumors | UNKNOWN | NCT04972422 |
| ZN-c3 | Other | Phase PHASE1 | Solid Tumors | UNKNOWN | NCT04972422 |
| Placebo | Other | Approved | Clostridium Difficile | TERMINATED | NCT02730325 |
| Serum-derived bovine immunoglobulin/protein isolate (SBI) | Other | Approved | Clostridium Difficile | TERMINATED | NCT02730325 |
| ZN-c5 | Other | Phase PHASE1 | Breast Neoplasms | COMPLETED | NCT04852419 |
| PillSense System | Other | Approved | Upper Gastrointestinal Bleeding | COMPLETED | NCT05631652 |
| PillSense System | Other | Approved | Upper Gastrointestinal Bleeding | COMPLETED | NCT05631652 |
| PillSense System | Other | Approved | Upper Gastrointestinal Bleeding | COMPLETED | NCT05631639 |
| PillSense System | Other | Approved | Upper Gastrointestinal Bleeding | COMPLETED | NCT05631639 |
| Standard of care | Other | Approved | Covid19 | COMPLETED | NCT04682041 |
| Bovine Plasma-Derived Immunoglobulin Concentrate | Other | Approved | Covid19 | COMPLETED | NCT04682041 |
| PICS in critically ill pediatric population | Other | Preclinical | Metabolism and Nutrition Disorder | TERMINATED | NCT03584399 |
| PICS in critically ill pediatric population | Other | Preclinical | Metabolism and Nutrition Disorder | TERMINATED | NCT03584399 |
| ZN-d5 | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT05127811 |
| ZN-d5 | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT05127811 |
| ZN-d5 | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT05127811 |
| PillSense | Other | Approved | UGI Bleed | COMPLETED | NCT05385224 |
| PillSense | Other | Approved | UGI Bleed | COMPLETED | NCT05385224 |
| PillSense | Other | Approved | UGI Bleed | COMPLETED | NCT05385224 |
| Medical food | Other | Preclinical | Metabolism | RECRUITING | NCT05647135 |
| Medical food | Other | Preclinical | Metabolism | RECRUITING | NCT05647135 |
| Medical food | Other | Preclinical | Metabolism | RECRUITING | NCT05647135 |
| Matching Placebo | Other | Approved | Healthy | COMPLETED | NCT02017405 |
| Serum-derived bovine immunoglobulin protein isolate (SBI) | Other | Approved | Healthy | COMPLETED | NCT02017405 |
| Supplemental Parenteral Nutrition (SPN) | Other | Approved | Parenteral Nutrition | RECRUITING | NCT06510348 |
| Supplemental Parenteral Nutrition (SPN) | Other | Approved | Parenteral Nutrition | RECRUITING | NCT06510348 |
| REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO] | Other | Phase PHASE3 | Postoperative Cognitive Dysfunction | RECRUITING | NCT07113483 |
| Midazolam | Other | Phase PHASE3 | Postoperative Cognitive Dysfunction | RECRUITING | NCT07113483 |
| REMIMAZOLAM BESYLATE 2.5 Mg in 1 mL INTRAVENOUS INJECTION, POWDER, LYOPHILIZED, for SOLUTION [BYFAVO] | Other | Phase PHASE3 | Postoperative Cognitive Dysfunction | RECRUITING | NCT07113483 |
| Midazolam | Other | Phase PHASE3 | Postoperative Cognitive Dysfunction | RECRUITING | NCT07113483 |
| EBP11-F5 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F1 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F4 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F2 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP22 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| Forteo 0.02 mg | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP05 | Other | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Rate-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| Volume-based EN | Other | Approved | Enteral Feeding | ACTIVE_NOT_RECRUITING | NCT05286177 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| PillSense™ | Other | Preclinical | Occult Gastrointestinal Bleeding | ENROLLING_BY_INVITATION | NCT06951490 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| NEMO-103 Injection | Other | Phase PHASE3 | Rotator Cuff Tear | ACTIVE_NOT_RECRUITING | NCT07057037 |
| EBP11-F5 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F1 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F4 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11-F2 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP22 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| EBP11 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| Forteo 0.02 mg | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| ZN-d5 | DRUG | Phase PHASE1 | Non-Hodgkin Lymphoma | TERMINATED | NCT05127811 |
| ZN-c3 | DRUG | Phase PHASE1 | Solid Tumors | UNKNOWN | NCT04972422 |
| ZN-c5 | DRUG | Phase PHASE1 | Breast Neoplasms | COMPLETED | NCT04852419 |
| Placebo of EBP05 | DRUG | Phase PHASE2 | Osteoporosis | COMPLETED | NCT04003467 |
| EBP05 | DRUG | Phase PHASE1 | Hypoparathyroidism | COMPLETED | NCT05965167 |
| NATPARA/NATPAR | DRUG | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT03516773 |
| EB612 (EBP05) | DRUG | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT03516773 |
| Oral PTH (1-34) | DRUG | Phase PHASE1 | Drug Safety and Bioavailability | COMPLETED | NCT02571140 |
| 160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women | DRUG | Phase PHASE3 | Chronic Respiratory Failure | COMPLETED | NCT00230984 |
| exercises on an ergometric bicycle 3 to 5 times a week | BEHAVIORAL | Phase PHASE3 | Chronic Respiratory Failure | COMPLETED | NCT00230984 |
| Oral dietary supplements (563 kcal/d), RESPIFOR | DRUG | Phase PHASE3 | Chronic Respiratory Failure | COMPLETED | NCT00230984 |
| education | BEHAVIORAL | Phase PHASE3 | Chronic Respiratory Failure | COMPLETED | NCT00230984 |
| placebo | DRUG | Phase PHASE1 | Drug Safety | COMPLETED | NCT02202603 |
| Teriparatide | DRUG | Phase PHASE1 | Drug Safety and Bioavailability | COMPLETED | NCT02571140 |
| EnteraBio's Oral Parathyroid Hormone (1-34) | DRUG | Phase PHASE2 | Hypoparathyroidism | COMPLETED | NCT02152228 |
Total products: 143